Lung Cancer

Sukhmani Padda, MD, assistant professor of medicine, Stanford University Medical Center, member, Stanford Cancer Institute, discusses therapy beyond osimertinib in the treatment of patients with EGFR-positive non–small cell lung cancer.

The FDA has expanded the indication for pemetrexed in combination with pembrolizumab and platinum-based chemotherapy for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer without EGFR or ALK alterations.

The Lung Cancer Master Protocol, known as the first precision medicine trial in lung cancer supported by the National Cancer Institute, has expanded to include patients with all types of non–small cell lung cancers.

Eric Vallieres, MD, medical director, Division of Thoracic Surgery, Swedish Cancer Institute, discusses future applications for surgery in the treatment of patients with lung cancer.

Mark A. Socinski, MD, executive medical director, AdventHealth Medical Group, discusses combination versus single-agent immunotherapy in patients with squamous non–small cell lung cancer.

Until more biomarkers are available, the use of tumor mutational burden with PD-L1 expression could help oncologists further personalize immunotherapy choices for patients with non–small cell lung cancer.

Mark A. Socinski, MD, provides an overview of treatment advances in the lung cancer landscape, and highlights where much-needed work still remains.

Findings from the PACIFIC trial have made a significant impact on the treatment of patients with unresectable stage III non–small cell lung cancer, especially in light of the history of treatment options in this setting.

Roy Decker, MD, PhD, associate professor of Therapeutic Radiology, Yale Cancer Center, discusses the current role of radiation therapy in the treatment of patients with non–small cell lung cancer.

Despite the rapidly expanding therapeutic options available in immunotherapy for patients with non-small cell lung cancer, there are still a number of drawbacks to treatment, explaining why not all patients respond to current treatment options.

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the eligibility criteria for immunotherapy trials in non–small cell lung cancer.

Data on many new treatment options have come forward over the past year highlighting the potential to treat more emerging oncogenic drivers impacting smaller subsets of patients with non–small cell lung cancer.

Eric Vallieres, MD, highlights the technological advances of lung cancer surgery and how this impacts the outlook for patients who are candidates for it.

Heather Wakelee, MD, associate professor of medicine (oncology), Stanford University Medical Center, discusses the current state of treatment in patients with non–small cell lung cancer.

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses traditional and emerging treatment approaches for patients with mesothelioma.

A growing focus on smaller oncogenic drivers in lung cancer has opened up new treatment options and many potential drugs in development for patients with less common alterations.

The treatment paradigm for EGFR-mutant non–small cell lung cancer has grown significantly with many EGFR TKIs now available to treat patients with this disease.

Rogerio Lilenbaum, MD, highlights the current treatment approaches for patients with EGFR-positive non–small cell lung cancer and shed light on the potential for immunotherapy in the space.

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses managing immune-related adverse events in lung cancer.

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the potential for immunotherapy in the treatment of patients with EGFR-positive non–small cell lung cancer.

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the role of antiangiogenesis in the treatment of patients with lung cancer.

Bristol-Myers Squibb has withdrawn its supplemental biologics license application for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the frontline treatment of patients with advanced non–small cell lung cancer with tumor mutational burden ≥10 mutations per megabase.

Clinical trial evidence is building for moving checkpoint blockade immunotherapy forward in the treatment timeline for non–small cell lung cancer, but improving patient selection for these therapies remains a key challenge.

D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses optimal treatment strategies for patients with ALK-mutated non–small cell lung cancer.

Janakiraman Subramanian, MD, discusses ongoing advances and remaining challenges in the field of lung cancer.